Browse by author
Lookup NU author(s): Professor John IsaacsORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Introduction: Gene expression profiling is rapidly becoming a useful and informative tool in a much needed area of research. Identifying patients as to whether they will respond or not to a given treatment before prescription is not only essential to optimise treatment outcome but also to lessen the economic burden that such drugs can have on healthcare resources. In rheumatoid arthritis (RA), there is of yet no genetic/genomic biomarker which can accurately predict response to TNF inhibitor biologics prior to treatment, despite much interest in this area. Multiple studies have reported findings on potential candidate genes; however, due to relatively small sample sizes or lack of sufficient validation, results have been disappointingly inconsistent. The aim of this research was to further explore the predictive value of a previously reported association between CD11c expression and response to the TNF inhibitor biologics, adalimumab and etanercept.Methods: Real-time qPCR was performed using whole blood RNA samples obtained from seventy-five rheumatoid arthritis patients about to commence treatment with a TNF inhibitor biologic drug, whose response status was determined at 3-month follow-up using the EULAR classification criteria. Relative quantification of CD11c using the comparative C-T method outputted differential expression between good-responders and non-responders as a fold-change.Results: Relative expression of CD11c in patients receiving TNF inhibitor biologics yielded a decrease of 1.025 fold in good-responders as compared to non-responders (p-value = 0.36). Upon stratification of patients dependent upon the specific drug administered, adalimumab or etanercept, similar findings to the full cohort were observed, decreases of 1.015 (p-value = 0.33) and 1.032 fold (p-value = 0.13) in good-responders compared to non-responders, respectively.Conclusion: The results from this study reveal that CD11c expression does not correlate with response to TNF inhibitor biologics when tested for within pre-treatment whole blood samples of rheumatoid arthritis patients.
Author(s): Smith SL, Eyre S, Yarwood A, Hyrich K, Morgan AW, Wilson AG, Isaacs J, Plant D, Barton A, Biol Rheumatoid Arthrit Genetics
Publication type: Article
Publication status: Published
Journal: Arthritis Research & Therapy
Year: 2015
Volume: 17
Online publication date: 14/12/2015
Acceptance date: 20/11/2015
Date deposited: 05/04/2016
ISSN (print): 1478-6354
ISSN (electronic): 1478-6362
Publisher: BioMed Central
URL: http://dx.doi.org/10.1186/s13075-015-0868-y
DOI: 10.1186/s13075-015-0868-y
Altmetrics provided by Altmetric
